A modern regulatory framework is the foundation of an innovative health care system that allows stakeholders to work together to deliver better outcomes for patients. To advance critical regulations toward this end, the U.S. Food and Drug Administration (FDA) announced last September that it would engage in a comprehensive review of its rules governing biopharmaceutical company communications related to unapproved uses of approved medicines. The FDA also sought input on this from key stakeholders over a two-day public hearing late last fall.
In the time since the public hearing, the agency has issued a final rule on “Intended Use” and released two draft guidances.
Update on “Intended Use” Final Rule
Last month, the FDA announced it would be extending the comment period for the final rule addressing the “Intended Use” of medical products for an additional 60 days (until July 18, 2017). This extension followed a delay in the effective date of the final rule as requested by PhRMA and other stakeholders due to concerns about the final rule that PhRMA, Medical Information Working Group (MIWG) and Biotechnology Innovation Organization (BIO) expressed in a citizen petition submitted in February.
Recommendations for a Path Forward
While we appreciate the draft guidance documents that were released by the agency in January, we believe the FDA should do more to facilitate effective communication from biopharmaceutical companies to key stakeholders, such as payers and health care providers, specifically when it comes to the ability of companies to communicate about medically accepted, unapproved uses of FDA-approved medicines.
Allowing for broader communication from biopharmaceutical companies to payers and health care providers about the most current, accurate and comprehensive information available on FDA-approved and investigational medicines can help these key stakeholders make more informed decisions for the benefit of patients. It can also support the move toward value-based contracts for pharmaceuticals by allowing the conversations needed to get to those contracts.
This is not to say that information sharing should occur without clear guardrails in place. The FDA plays a critical role in ensuring the safety and efficacy of new medicines and new uses of previously approved medicines—an understanding that is recognized by the industry in the principles jointly proposed by PhRMA and BIO last year. That said, while the FDA’s role as a gatekeeper is critical, the agency must balance this role with the benefit to patients when key stakeholders are fully educated about all available treatment options.
We look forward to working with the FDA to develop a regulatory regime that supports communication of truthful and non-misleading information from biopharmactical companies to key stakeholders in the interest of public health.
Read PhRMA’s full comments to the FDA on the draft gudiance on communications with payors, draft guidance on communications consistent with labeling, or responding to the public hearing, or see the citizen petition.
Michelle Drozd
Michelle Drozd is a former Deputy Vice President in the Policy and Research department at the PhRMA.
Michelle Drozd
Incomplete evaluations undermine patient access to transformational medicine
Innovative contracts continue to gain traction and improve quality of care
Growth in innovative, value-based contracts holds promise for the health system and for patients
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
ICYMI: Fighting for a cure to ALS
"If Washington isn’t careful, we might leave innovation behind"
5 Ways to improve ICER’s value assessment framework
Assessing value top of mind at ISPOR 2019
Giving patients a voice: PhRMA launches Voters for Cures to support the next generation of treatments and cures
New report shows nearly 300 cell and gene therapies in development
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
New report shows more than 300 skin disease medicines in development
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
Number of value-based contracts continues to rise
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Event next week: Supporting the next generation of lifesaving medicines
How ICER’s assessment of a new class of migraine treatments fails patients
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
Event tomorrow: Improving patient access to lifesaving medicines
Reality check: Value-based contracts are good for patients
Video: Barriers to results-based contracts
Improving care quality by engaging patients in shared decision making
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
Clarity around anti-kickback statute needed to promote innovative payment arrangements
ICYMI: Report highlights increasing prevalence for Alzheimer’s disease
Video: What is a results-based contract?
New report and event examine the new era of vaccines
A new era in cancer
2017 Research & Hope Awards honor innovators in mental health
PhRMA Foundation recognizes inaugural Challenge Award recipients
The journey to better health care requires a holistic view
Working to harness the power of the body’s own immune system
Medicare Monday: How Part B has evolved over the years
Going boldly together: New advancements and new anniversaries
Examining the brain in The New Era of Medicine
Fighting multiple sclerosis: New Together ad illuminates the journey of patient & scientist
ICYMI: Avalere and FasterCures develop new value framework from patient perspective
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
Mental health in the New Era of Medicine
This is not a special effect: New video shows the destruction of a rogue cell
RA medicines often demonstrate far greater benefits to patients than initially understood
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
Exploring the new era of medicine
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
Modernizing FDA regulations to advance a value-driven health care system
Value-Driven Health Care
GoBoldly
Modernizing FDA regulations to advance a value-driven health care system
Modernizing FDA regulations to advance a value-driven health care system